HPGC(SH:600664) Sou Hu Cai Jing·2025-08-25 11:06Group 1 - The core point of the article highlights the recent performance of Harbin Pharmaceutical Group Co., Ltd. (哈药股份), noting a stock price of 3.92 yuan, a decrease of 2.97% as of August 25, 2025 [1] - The company reported total revenue of 8.125 billion yuan for the first half of 2025, a year-on-year decrease of 0.21%, and a net profit attributable to shareholders of 260 million yuan, down 24.37% year-on-year [1] - The company's liquidity ratios include a current ratio of 1.440 and a quick ratio of 1.179, with a debt-to-asset ratio of 54.71% [1] Group 2 - Harbin Pharmaceutical Group has made investments in 30 companies and participated in 3,232 bidding projects [2] - The company holds 2 trademark registrations and 67 patents, along with 21 administrative licenses [2]